PUBLICATION AND RESOURCES

PUBLICATIONS

5.3.2021 | Clinical Cancer Research
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Landon C. Brown1, Susan Halabi1,2, Joseph D. Schonhoft3, Qian Yang2, Jun Luo4, David M. Nanus5, Paraskevi Giannakakou5, Russell Z. Szmulewitz6, Daniel C. Danila5,7, Ethan S. Barnett7, Emily A. Carbone7, Jimmy L. Zhao7, Patrick Healy8, Monika Anand1, Audrey Gill3, Adam Jendrisak3, William R. Berry1, Santosh Gupta9, Simon G. Gregory9, Richard Wenstrup3, Emmanuel S. Antonarakis10, Daniel J. George1, Howard I. Scher5,7, and Andrew J. Armstrong1
5.3.2021 | Clinical Cancer Research
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

H.I. Scher a,b,,1, A.J. Armstrong c,*,1, J.D. Schonhoft d, A. Gill d, J.L. Zhao a, E. Barnett a, E. Carbone a, J.Lud, E.S. Antonarakis e, J. Luo e, S. Tagawa b, C.H. dos Anjos a, Q. Yang f, D. George c, R. Szmulewitz f,g, D.C. Danila a,b, R. Wenstrup d, M. Gonen a,2,
S. Halabi c,f,2
5.3.2021 | Clinical Cancer Research
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer

Joseph D. Schonhoft1, Jimmy L. Zhao2,3, Adam Jendrisak1, Emily A. Carbone4, Ethan S. Barnett4, Melanie A. Hullings4,5, Audrey Gill1, Ramsay Sutton1, Jerry Lee1, Angel E. Dago1, Mark Landers1, Samuel F. Bakhoum3,6, Yipeng Wang1, Mithat Gonen7, Ryan Dittamore1, and Howard I. Scher2,8
10.28.2020 | JCO Precision Oncology
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM1; Jun Luo, PhD2; David M. Nanus, MD3; Paraskevi Giannakakou, PhD3; Russell Z. Szmulewitz, MD4; Daniel C. Danila, MD3,5; Patrick Healy, MS; Monika Anand, PhD1; William R. Berry, MD1; Tian Zhang, MD1; Michael R. Harrison, MD1; Changxue Lu, MM, PhD2; Yan Chen, BM, PhD2; Giuseppe Galletti, MD, PhD3; Joseph D. Schonhoft, PhD7; Howard I. Scher, MD5; Richard Wenstrup, MD7; Scott T. Tagawa, MD3; Emmanuel S. Antonarakis, MD2,8; Daniel J. George, MD1; and Susan Halabi, PhD8
FULL PUBLICATION LIST

Resources

SCIENTIFIC POSTERS

3.3.2023
Improved Sensitivity in Identification of ER and HER2 Expressing Metastatic Breast Cancer with a Combination of Cell & Cell-free Liquid Biopsy Analysis
12.10.2022
A Single-Center Prospective Cohort Study to Evaluate Circulating Tumor Cells as a Monitoring Tool in Women with Breast Cancer Treated with Neoadjuvant Chemotherapy
12.9.2022
TROP2 and HER2 Expression by Liquid Biopsy in Women with Metastatic Triple Negative Breast Cancer
12.9.2022
Liquid Biopsy Identification of ERBB2 Amplified and HER2 Expressing Metastatic Breast Cancer: Comparison and Combination of Cell and Cell-free Platforms
All SCIENTIFIC POSTERS

PACKAGE INSERTS

AR-V7 Blood Collection Kit Package Insert (Kit FM-00049 and FM-00076)
CE Mark Blood Collection Kit Package Insert (Kit FM-000107)
CTC Liquid Biopsy Blood Collection Kit Requisition Form (LBL-00081)
ALL INSERTS

EPIC PODCAST: FEATURED

6.13.2019
EPISODE 02 | LAUREN LEIMAN

In Episode 2 of Innovations in Cancer, we speak with Lauren Leiman, executive director at BloodPAC, the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, launched October 2017, to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. Lauren discusses the collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies with the goal to standardize liquid biopsies to improve outcomes for patients.

Listen Now
MORE EPISODES